Drug Type Monoclonal antibody |
Synonyms NNV 029, NNV029 |
Target |
Mechanism CD37 modulators(Leukocyte antigen CD37 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Burkitt Lymphoma | Preclinical | NO | 11 Dec 2022 |